根据 7 位华尔街分析师的预测,Revenio Group Oyj 的收入预期范围从 $31.18M 到 $27.34M
Revenio Group Oyj 的盈利质量评分是多少?
Revenio Group Oyj 的盈利质量评分为 /。该评分基于盈利能力、增长、现金生成与资本分配以及杠杆四个维度。
Revenio Group Oyj 何时发布财报?
Revenio Group Oyj 的下一份财报预计在 2026-07-27 发布
Revenio Group Oyj 的预期收益是多少?
根据华尔街分析师的预测,Revenio Group Oyj 的预期收益为 $28.29M
Revenio Group Oyj 是否超出收益预期?
Revenio Group Oyj 最近的收益为 $27.3M,未达预期 预期。
关键数据
前收盘价
$16.41
开盘价
$16.41
当日区间
$16.41 - $16.41
52周范围
$16.41 - $31.47
交易量
1.0K
平均成交量
31
股息收益率
--
每股收益(TTM)
0.68
市值
$477.3M
什么是 REVENIO GROUP OYJ?
Revenio Group Oyj engages in ophthalmic diagnostics and the manufacture and sale of ophthalmic devices. The company is headquartered in Vantaa, Etela-Suomen and currently employs 246 full-time employees. The company went IPO on 2003-01-01. The Company’s activities are divided into two business areas: Revenio Health Tech, which is responsible for the design, manufacture and sale of tonometers and bone density measurement devices; as well as Revenio Technology and Services, which provides contact center services for material handling systems. The company distributes products in a range of countries, including the United States, Canada, Australia, Japan and India. Furthermore, the Company is a parent of Done Medical Oy, Kauhajoen Sisalogistiikka Oy, Icare Finland Oy, Oscare Medical Oy and Midas Touch Oy, among others.